证券代码：688488 证券简称：艾迪药业 公告编号：2026-013 本事项不会影响公司的正常经营，敬请广大投资者注意投资风险。 特此公告。 江苏艾迪药业集团股份有限公司董事会 江苏艾迪药业集团股份有限公司（以下简称"公司"）根据当地税务部门通 知，需补缴税款共计约 1,995.20 万元，本次补缴税款不涉及滞纳金，不涉及行政 处罚。现将有关情况公告如下： 一、基本情况 根据扬州市税务部门的通知，公司需补缴税款共计约 1,995.20 万元。公司将 按照要求于 15 日内将上述税款全部缴纳完毕。本次补缴税款不涉及滞纳金，不 涉及行政处罚，上述税款计入 2025 年度当期损益。 二、对公司的影响及风险提示 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》相 关规定，上述补缴税款事项不属于前期会计差错，不涉及前期财务数据追溯调整。 公司补缴税款计入 2025 年当期损益，预计影响公司 2025 年度利润总额约 1,995.20 万元，最终以 2025 年度经审计的财务报表为准。 江苏艾迪药业集团股份有限公司 关于补缴税款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 ...

证券代码：688488 证券简称：艾迪药业 公告编号：2026-012 江苏艾迪药业集团股份有限公司 关于 ACC085 注射液临床试验申请获得受理的 自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、江苏艾迪药业集团股份有限公司（以下简称"公司"）及全资子公司泸 州艾迪医药技术有限公司于近日收到国家药品监督管理局（以下简称"国家药监 局"）签发的境内生产药品注册临床试验的《受理通知书》。 2、本次申请为新药临床试验申请，在临床试验申请获得受理后，若在受理 之日起 60 日内未收到药品审评中心的否定或质疑意见的，公司可以按照提交的 方案开展临床试验。新药审评审批时间、审批结果及后续临床试验的研究进程、 研究结果和未来产品市场竞争形势均存在诸多不确定性，且本次事项短期内对公 司经营业务不会产生较大的影响，敬请广大投资者谨慎决策，注意防范投资风险。 一、药品相关情况 产品名称：ACC085 注射液 适应症：用于有 HIV-1 感染风险的成人和体重至少 35kg 青少年进行暴露前 预防(PrEP ...

一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 证券代码：688488 证券简称：艾迪药业 公告编号：2026-014 江苏艾迪药业集团股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 经江苏艾迪药业集团股份有限公司（以下简称"公司"）财务部门初步测算： 1、预计公司 2025 年度全年营业收入约 72,101.19 万元，较上年度相比，将 增加约 30,320.72 万元，同比增加约 72.57%；其中，抗 HIV 创新药收入预计为 28,531.45 万元，同比预计增加 90.34%；控股子公司南京南大药业有限责任公司 （以下简称"南大药业"）的收入预计为 29,983.93 万元，报表合并口径同比预 计增加 227.38%（注：公司自 2024 年 9 月开始合并南大药业经营数据，南大药 业对比口径中 2024 年为 9 至 12 月数据，2025 年为全年数据）； 2、预计 2025 年度实现归属于 ...

（原标题：艾迪药业(688488.SH)：补缴税款共计约1995.20万元） 格隆汇1月25日丨艾迪药业(688488.SH)公布，根据扬州市税务部门的通知，公司需补缴税款共计约 1,995.20万元。公司将按照要求于15日内将上述税款全部缴纳完毕。本次补缴税款不涉及滞纳金，不涉 及行政处罚，上述税款计入2025年度当期损益。 ...

Core Viewpoint - Eddie Pharmaceuticals (688488.SH) expects a significant reduction in losses for the fiscal year 2025, with projected revenues increasing substantially compared to the previous year [1] Financial Performance - The company anticipates total revenue for 2025 to be approximately 721.01 million yuan, an increase of about 303.21 million yuan or 72.57% year-on-year [1] - Revenue from innovative anti-HIV drugs is expected to reach approximately 285.31 million yuan, reflecting a year-on-year increase of 90.34% [1] - The revenue from the subsidiary Nanjing Nanda Pharmaceutical Co., Ltd. is projected to be around 299.84 million yuan, with a year-on-year increase of 227.38% [1] Profitability Outlook - The company forecasts a net loss attributable to shareholders of approximately 16.00 million to 24.00 million yuan for 2025, which represents a reduction in losses of about 125.20 million to 117.20 million yuan, translating to a year-on-year decrease in loss margin of approximately 88.67% to 83.00% [1] - The expected net loss attributable to shareholders, excluding non-recurring gains and losses, is projected to be around 17.20 million to 25.20 million yuan, indicating a reduction in losses of approximately 131.25 million to 123.25 million yuan, with a year-on-year decrease in loss margin of about 88.41% to 83.02% [1]

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), anticipates a significant increase in revenue for the fiscal year 2025, with a projected total revenue of approximately 721.01 million yuan, representing a year-on-year increase of about 72.57% [1] Revenue Projections - The expected revenue from innovative anti-HIV drugs is projected to be approximately 285.31 million yuan, reflecting a year-on-year increase of 90.34% [1] - The revenue from the subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., is expected to reach approximately 299.84 million yuan, with a year-on-year increase of 227.38% [1] Profitability Outlook - The company forecasts a net loss attributable to shareholders of approximately 16 million to 24 million yuan for 2025, which is a reduction in loss of about 125.20 million to 117.20 million yuan compared to the previous year, resulting in a year-on-year decrease in loss margin of approximately 88.67% to 83.00% [1] - The expected net loss attributable to shareholders, excluding non-recurring gains and losses, is projected to be around 17.20 million to 25.20 million yuan, indicating a reduction in loss of approximately 131.25 million to 123.25 million yuan compared to the previous year, with a year-on-year decrease in loss margin of about 88.41% to 83.02% [1]

Core Viewpoint - The company anticipates a significant increase in revenue for the fiscal year 2025, driven by its innovative HIV drug and the performance of Nanda Pharmaceutical, despite projected net losses narrowing compared to the previous year [1] Revenue Projections - The company expects total revenue of approximately 721.01 million yuan for 2025, representing a year-on-year increase of about 72.57% [1] - Revenue from the innovative HIV drug is projected to be around 285.31 million yuan, reflecting a year-on-year growth of 90.34% [1] - Nanda Pharmaceutical's revenue is expected to reach approximately 299.84 million yuan, with a consolidated year-on-year increase of 227.38% [1] Profitability Outlook - The net profit attributable to the parent company is projected to be between -16 million yuan and -24 million yuan, indicating a year-on-year reduction in loss margin by approximately 88.67% to 83.00% [1] - The non-recurring net profit is expected to range from -17.2 million yuan to -25.2 million yuan, with a year-on-year decrease in loss margin of about 88.41% to 83.02% [1] - The improvement in profitability is primarily attributed to an increase in gross margin from core business operations, despite a rise in selling expenses [1]

艾迪药业公告，公司及全资子公司泸州艾迪医药技术有限公司于近日收到国家药品监督管理局签发的境 内生产药品注册临床试验的《受理通知书》。产品名称为ACC085注射液，适应症为用于有 HIV-1感染 风险的成人和体重至少35kg青少年进行暴露前预防(PrEP)的 HIV-1衣壳抑制剂。 ...

融资余额降幅前20只个股 证券时报·数据宝统计显示，截至1月22日，沪市两融余额13767.95亿元，较前一交易日增加21.87亿元； 深市两融余额13391.33亿元，较前一交易日增加17.66亿元；北交所两融余额89.85亿元，较前一交易日 减少0.62亿元；深沪北两融余额合计27249.13亿元，较前一交易日增加38.90亿元。 具体到个股来看，融资余额出现增长的股票有1756只，占比46.55%，其中，311股融资余额增幅超过5% 。融资余额增幅最大的是中超控股，该股最新融资余额6.12亿元，较前一交易日增幅达119.34%；股价 表现上，该股当日上涨10.04%，表现强于沪指；融资余额增幅较多的还有华新精科、潍柴重机，融资 余额增幅分别为57.00%、51.33%。 融资余额增幅前20只个股中，从市场表现来看，平均上涨6.95%，涨幅居前的有特瑞斯、三角防务、富 满微，涨幅分别为29.98%、19.99%、15.19%。跌幅居前的有聚胶股份、广钢气体、汇隆活塞，跌幅分 别为8.16%、6.44%、5.05%。 融资余额增幅前20只个股 | 代码 | 简称 | 最新融资余额（万 | 较前一个交易日增减 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.73% on January 22, with Aidi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Individual Stock Performance - Wanze Co., Ltd. (000534) saw a significant increase of 6.53%, closing at 27.74 with a trading volume of 337,600 shares and a transaction value of 917 million [1] - Aidi Pharmaceutical (688488) reported a substantial decrease of 13.48%, closing at 18.17 with a trading volume of 281,700 shares and a transaction value of 537 million [2] - Other notable performers included ST Sihuan (000518) with a rise of 3.03% and Kanghong Pharmaceutical (002773) with a decline of 3.03% [1][2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 551 million from institutional investors, while retail investors saw a net inflow of 279 million [2] - The main capital inflow was observed in Wanze Co., Ltd. with 81.16 million from institutional investors, while Kanghong Pharmaceutical had a net outflow of 50.59 million from retail investors [3]